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Abstract
Background: Minichromosome maintenance (MCM) proteins are essential for the initiation of
DNA replication and have been found to be relevant markers for prognosis in a variety of tumours.
The aim of this study was to assess the proliferative activity of diffuse large B-cell lymphoma
(DLBCL) in tissue microarray (TMA) using one of the minichromosome maintenance proteins
(Mcm2) and to explore its potential value to predict prognosis.
Methods: Immunohistochemistry for Mcm2 was performed on TMAs constructed from 302 cases
of DLBCL. A monoclonal mouse antibody was used after heat induced antigen retrieval. Mcm2
expression was scored quantitatively. Positivity for Mcm2 was defined as presence of nuclear
expression of Mcm2 in greater than or equal to 40 % of tumour cells. A statistical analysis was
carried out of the association of Mcm2 and the clinico-pathological characteristics.
Results: Mcm2 expression was clearly evident in the nuclei of proliferating non-neoplastic cells and
tumour cells. Positivity for Mcm2 was found in 46% (98/211) of analysable cases. A significant
correlation existed between Mcm2 expression and presence of bulky disease (p = 0.003). Poor
disease specific survival was observed in patients with DLBCL positive for Mcm2 expression in the
univariate analysis (p = 0.0424).
Conclusion: Mcm2 expression can be used to assess tumour proliferation and may be useful as
an additional prognostic marker to refine the prediction of outcome in DLBCL.
Background
In Western countries, diffuse large B-cell lymphoma
(DLBCL) is the most common type of mature B-cell lym-
phomas with a frequency of approximately 30 to 40% [1].
DLBCL is an aggressive but potentially curable disease.
However, only about 40 to 45% of patients are cured with
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combination chemotherapy [2]. Currently, the Interna-
tional Prognostic Index (IPI) is the generally accepted pre-
dictor of prognosis [3]. In order to avoid over-treatment of
some patients and identify patients at high-risk for early
relapse or poor response to standard treatment, individu-
alised prediction of prognosis becomes more and more
important.
A number of biological markers have been studied for
their predictive potential, but none has become univer-
sally accepted [4-7]. Gene expression profiling has helped
to identify at least two subgroups of DLBCL, one with a
germinal centre signature and the other with an activated
B-cell signature, which show distinct clinical outcomes
[3,8].
The proliferative capacity of neoplastic cells is an impor-
tant feature of growing tumours. Assessment of cell prolif-
eration may provide both pathologists and clinicians with
more objective prognostic information [9,10]. Expression
of Ki-67 as assessed by immunohistochemistry has
become the standard proliferation marker [11-13]. In
lymphoid neoplasms, it is controversial whether Ki-67 is
a reliable prognostic indicator [14-17]. In DLBCL, a high
proliferation index has been associated with an unfavour-
able clinical outcome in some studies [18]. Despite the
Table 1: Details of clinico-pathologic data and expression of Mcm2 in diffuse large B-cell lymphomas
Variable Categorisation n analysable %
Clinico-pathologic data:
Age at diagnosis
median 67 years (interquartile range 54–75 years)
<65 years 69 43.1
≥65 years 91 56.9
Gender
male 97 53.3
female 85 46.7
Ann Arbor stage
12 7 1 7 . 3
25 0 3 2 . 1
33 4 2 1 . 8
44 5 2 8 . 8
International prognostic index (IPI)
02 1 . 3
16 6 4 3 . 4
22 9 1 9 . 1
33 2 2 1 . 1
42 3 1 5 . 1
Bone marrow involvement
yes 44 28.6
no 110 71.4
Extranodal involvement
yes 54 35.8
no 97 64.2
Bulky disease
yes 94 64.4
no 52 35.6
Chemotherapy
no therapy 7 4.6
CHOP 69 45.1
other 77 50.3
Serum levels of LDH at diagnosis
median 306 U/l (interquartile range 185–443 U/l)
<300 U/l 61 49.2
≥300 U/l 63 50.8
Immunohistochemistry:
Mcm2 immunoreactivity
median 38% (interquartile range 29%–48%)
<40% 113 53.6
≥40% 98 46.4BMC Cancer 2005, 5:162 http://www.biomedcentral.com/1471-2407/5/162
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extensive use of Ki-67, its functional significance still
remains unclear [19]. It has been suggested, that Ki-67
plays a role in the ribosome biosynthesis rather than
being directly responsible for cell proliferation [20,21].
Therefore, detecting markers directly involved in DNA
replication might be a more precise method to evaluate
the proliferative behaviour of a tumour.
The minichromosome maintenance (MCM) protein fam-
ily consists of six members of DNA-binding proteins [22].
MCM proteins stand at the end of many signalling path-
ways involved in cell proliferation [23]. They ensure that
synthesis of DNA is initiated only once during each cell
cycle. All six proteins are abundant throughout the cell
cycle and are broken down rapidly on differentiation or
more slowly in quiescence [24,25]. Expression is only
observed in cycling cells, there is no expression in quies-
cent and differentiating cells [25-28].
Antibodies for detection of MCM proteins in routinely
processed tissue specimen have been found superior to Ki-
67 in defining the proliferative compartments in both
normal and abnormal human tissues [27,29-32]. Immu-
nohistochemical assessment of all six MCM proteins has
been observed to produce similar results in a range of tis-
sue sections [33]. MCM proteins have been promoted as
markers for cancer screening, surveillance and prognosis
[27,29-31,34-36]. We used a specific monoclonal anti-
body directed against Mcm2 and a previously validated
tissue microarray (TMA) with tissue samples of a large
number of DLBCL [37]. Tissue microarrays are highly effi-
cient for the investigation of large series of neoplasms
including lymphoma [37-39].
The aim of this study was to systematically investigate if
the analysis of Mcm2 expression might provide a novel
tool to assess the proliferation of DLBCL and predict clin-
ical outcome in patients with this disease.
Methods
Construction of tissue microarrays and acquisition of 
clinico-pathologic data
Tissue microarrays were constructed as described previ-
ously [39,40]. The TMAs contained a total of 302 tissue
samples from tumours, which had been classified prior to
this study as diffuse large B-cell lymphomas according to
the WHO classification [1]. All samples had been
obtained at the time of diagnosis, before any treatment
had been given. Four different TMAs were constructed,
each containing tumour samples from different his-
topathologic institutions (Basel, Bologna, Innsbruck,
Zurich). Clinical data of patients with DLBCL at time of
primary diagnosis and follow-up had been obtained by
reviewing the charts. Clinico-pathologic data of patients
at time of diagnosis are detailed in table 1. Retrieval of tis-
sue and clinical data was performed according to the reg-
ulations of the local institutional review board and data
safety laws.
Table 3: Univariate analysis of factors regarding disease specific 
survival
Tumor-related 
death
Variable Categorisation n events pa
Clinico-pathologic data:
Age at diagnosis
<65 years 44 20 0.0805
≥65 years 77 43
Gender
male 64 31 0.4220
female 59 34
Ann Arbor Stage
11 9 6 0.0026
23 7 1 6
32 7 1 5
43 9 2 7
International prognostic index
02 0 <0.0001
14 6 1 6
22 4 1 1
32 5 2 0
42 2 1 6
Extranodal involvement
no 47 24 0.9997
yes 70 36
Bulky disease
no 73 36 0.3135
yes 39 20
Serum levels of LDH at diagnosis
<300 U/l 38 19 0.0133
≥300 U/l 54 31
Immunohistochemistry:
Mcm2 immunoreactivity
<40% 52 21 0.0424
≥40% 36 22
a Log rank test; bold face representing significant data.
Table 2: Performance of metric variables in prediction of 
mortality using the AUROC (area under the receiver operating 
characteristic curve) method
Mcm2 IHCc LDHd
Optimum cutoff value 39.5% 306 U/l
Sensitivityb 0.512 0.620
Specificityb 0.696 0.476
AUROCa 0.582 0.553
95% confidence interval 0.462–0.702 0.434–0.672
p (asymtptotic significance) 0.182 0.384
a AUROC, area under the receiver operating characteristic curve.
b sensitivity and specificity were calculated for the cutoff, which 
represented the best discrimination as derived from the ROC curves.
c IHC: immunohistochemistry
d LDH: lactate dehydrogenaseBMC Cancer 2005, 5:162 http://www.biomedcentral.com/1471-2407/5/162
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Immunohistochemistry
Four-micrometre sections of the TMA blocks were cut to
adhesive-coated slides (Instrumedics Inc, Hackensack, NJ,
USA) and stained using standard procedures. Briefly,
immunohistochemical studies utilized an avidin-biotin
peroxidase method with diaminobenzidine chroma-
togen. After heat induced antigen retrieval (microwave
oven for 30 min at 250 W) immunohistochemistry was
carried out in a NEXES immunostainer (Ventana, Tucson,
AZ). The following primary antibody was used: BM28
(mouse monoclonal, clone 46, BD Biosciences, San Jose,
US, final dilution 1:3000). The dilution had been estab-
lished using adequate controls. Negative controls were
obtained by omitting the primary antibody. The slides
were evaluated without knowledge of clinical data. At
least 10% of cases were re-evaluated by a second observer.
Only cases containing clearly recognisable tumour tissue
were analysed. One-hundred cells were assessed in each
tumour core and the percentage of positive cells (i.e. cells
with a distinct staining) was calculated. If a biopsy core
contained less than 100 cells as many neoplastic cells as
possible were evaluated. If more than one core from the
same tumour was available the results were averaged.
Cases were defined positive for Mcm2 if ≥40 % of
tumours cells showed distinct nuclear staining. The deter-
mination of cut-off levels was based on the analysis of the
area under the receiver operating characteristic curve
(AUROC) as described below and as detailed in table 2.
Statistical analysis
Statistical analyses were performed using SPSS version
10.0 (SPSS, Chicago, IL). Differences were considered sta-
tistically significant if P values were <0.05. Receiver oper-
ating characteristic (ROC) curves by plotting sensitivity
versus (1-specificity) were used to evaluate the diagnostic
performance of parameters at various cut-off points. An
AUROC closer to 1 indicates greater discriminatory
power, whereas an AUROC of 0.5 denotes no diagnostic
potential. The optimum cut-off was calculated as the max-
imum value of sensitivity multiplied by specificity. Sensi-
tivity and specificity were calculated according to standard
formulas for the cut-off that represented the best discrim-
ination derived from the ROC curves. The cut-off value
representing the best discrimination derived from the
ROC analysis was chosen for categorization of metric var-
iables (LDH (lactate dehydrogenase) and expression of
Mcm2). A statistical association between clinico-patho-
logic parameters and Mcm2 expression was tested using a
two-sided Fisher's exact test. Disease specific survival
(DSS) curves were calculated using the Kaplan-Meier
method with significance evaluated by two-sided log-rank
statistics. For DSS analysis, patients were censored at the
time of their last clinical follow-up appointment or at
their date of death not related to the tumour. A stepwise
multivariable Cox regression model was adjusted, testing
the independent prognostic relevance of Mcm2 positivity.
The limit for reverse selection procedures was P = 0.1. The
proportionality assumption for all variables was assessed
with log-negative-log survival distribution functions.
Results
Clinico-pathologic data
Clinical follow-up data were available for 123 of 302
(40.7 %) patients with a median follow-up period of 23.5
months (range 1 to 177 months). The median follow-up
for censored patients was 28.5 months. Clinico-patho-
logic parameters associated with poor disease specific sur-
vival were Ann Arbor stage (p = 0.0026), IPI (p < 0.0001),
and serum LDH ≥300 U/l (p = 0.0133) according to the
univariate analysis. The optimum cut-off level for LDH
Immunohistochemistry Figure 1
Immunohistochemistry. Figure 1A: Immunohistochemical 
staining of Mcm2 in a non-neoplastic lymph node. Mcm2-
expression is found in the majority of cells in the germinal 
centre; only a few cells in the mantle zone are positive for 
Mcm2. Figure 1B: Immunohistochemical staining of Mcm2 in 
diffuse large B-cell lymphoma. This case is positive for Mcm2-
expression with more than 40% of tumour cells expressing 
this marker.
Figure 1A
Figure 1BBMC Cancer 2005, 5:162 http://www.biomedcentral.com/1471-2407/5/162
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had been established at 306 U/l (AUROC method) and a
cut-off of 300 U/l was used for further statistical analysis.
Age at diagnosis and gender of patients did not make an
impact on DSS. Neither the presence of bone marrow
involvement, extranodal involvement nor bulky disease at
presentation was statistically relevant for DSS.
The results of the univariate analysis are presented in table
3.
Immunohistochemistry
Investigation of Mcm2 expression was informative in 69.9
% (211/302) of cases. Mcm2 expression in ≥40% of cells
was detected in 46.4 % (98/211) of DLBCL. Mcm2 was
clearly evident in the nuclei of tumour cells with low back-
ground staining. In non-neoplastic lymphoid tissue,
which was used as a positive control and for establishing
the appropriate staining protocols, expression of Mcm2
was mainly found in the germinal centres harbouring pro-
liferating cells; expression in the mantle zone and parafol-
licular zone was negligible (Figure 1A). Identical results
have previously been described [41].
The optimum cut-off for Mcm2 expression was calculated
as 39.5 % of cells using the AUROC method. For practical
reasons, a cut-off level of 40 % was chosen and patients
were divided into two subgroups accordingly (positive:
protein expression ≥40 % of cells; negative: protein
expression <40 % of cells). For descriptive data analysis,
all relevant variables were compared with Mcm2 expres-
sion (table 4). A representative image of immunohisto-
chemical expression of Mcm2 in DLBCL is shown in
figure 1B.
Prognostic significance
Disease specific survival was compared between tumours
positive and negative for Mcm2 by univariate log-rank sta-
tistics. Positivity for Mcm2 was associated with shorter
DSS (p = 0.0424) (table 3; figure 2). However, when
Mcm2 positivity was tested in the multivariate analysis in
Table 4: Clinico-pathologic and immunohistochemical parameters in relation to Mcm2 immunoreactivity
Mcm2 immunoreactivity
Variable Categorisation n analysable negative (<40%) positive (≥40%) pa
Clinico-pathologic data:
Age at diagnosis
< 6 5  y e a r s 4 72 72 0 1 . 0 0 0
≥6 5  y e a r s 6 33 72 6
Gender
male 72 39 33 0.593
female 57 34 23
Ann Arbor Stage
1 15 10 5 0.342
2 3 41 51 9
32 3 1 4 9
4 3 52 21 3
International prognostic index
0 2 2 0 0.122
1 4 82 72 1
22 1 1 4 7
32 0 1 3 7
41 4 4 1 0
Bone marrow involvement
no 72 39 33 0.414
y e s 3 52 21 3
Extranodal involvement
no 40 27 13 0.103
y e s 6 23 13 1
Bulky disease
no 62 44 20 0.003
y e s 3 51 32 2
Serum levels of LDH at diagnosis
< 3 0 0  U / l 4 22 31 9 0 . 5 0 5
≥3 0 0  U / l 4 12 61 5
a two-sided Fisher's exact test; bold type representing significant data.BMC Cancer 2005, 5:162 http://www.biomedcentral.com/1471-2407/5/162
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combination with LDH, IPI, and Ann Arbor stage it did
not retain its prognostic value (p = 0.546). LDH was not
found to be of prognostic relevance in the multivariate
analysis as well (p = 0.063). Both IPI (p = 0.010) and Ann
Arbor stage (p = 0.025) were significant prognostic mark-
ers in the multivariate analysis with respect to disease spe-
cific survival.
Discussion
Cell proliferation is essential for the growth of any type of
malignancy. Analysis of cell proliferation applying anti-
bodies specifically detecting members of the MCM pro-
tein family has been proposed as a novel method for cell
cycle assessment which may be of diagnostic and prog-
nostic value in the histopathologic assessment of neo-
plasms. Other proliferation markers such as the widely
used Ki-67 and proliferating cell nuclear antigen (PCNA)
are probably not as effective as MCM proteins for this pur-
pose, as Ki-67 is absent in early G1-phase, its function still
remains unknown [42] and PCNA is less specific for deter-
mining proliferation since it is also present during DNA
repair processes [43].
Analysis of MCM proteins by means of immunohisto-
chemistry has been shown to be of prognostic value in a
diverse range of human malignancies [30,34,44-51]; in
lymphoma however, high expression of Mcm2 has been
described in DLBCL, but so far data have never been eval-
uated with respect to clinical outcome [41].
Therefore we focused on the evaluation of Mcm2 expres-
sion in a large collective of clinically well documented
patients with DLBCL using tissue microarray technology
and immunohistochemistry. 46.4% of DLBCL showed
positivity for Mcm2 defined as expression in ≥40% of
tumour cells. Positivity was significantly associated with
shorter disease specific survival in the univariate analysis
(p = 0.0424). However, when tested in the multivariate
analysis, it did not retain its prognostic value (p = 0.546).
This finding may be attributable to the fact, that besides
proliferation, a number of other factors not included into
the clinico-pathological parameters of our analysis (such
as concomitant morbidity) may influence disease specific
survival. Therefore, assessment of Mcm2 expression may
still be useful as an additional prognostic marker in con-
junction with other established prognostic parameters.
Conclusion
In summary, expression of Mcm2 in ≥40% of tumour cells
was found to be a negative prognostic marker for disease
specific survival in this large series of DLBCL. Protein
expression of MCM proteins can easily be evaluated in
routinely processed tissue specimen using specific anti-
bodies in daily routine practice. Assessment of MCM pro-
tein expression may be used as a marker of proliferation
as well as a potentially prognostic indicator, and further
work in this area is warranted.
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